{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:16:34Z","timestamp":1789787794731,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":165,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"name":"Muscular Dystrophy Campaign"},{"name":"Great Ormond Street Children\u2019s Charity"},{"name":"Medical Research Council"},{"name":"NHS National Specialised Commissioning Team (Rare Neuromuscular Disorders)"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.nmd.2012.11.004","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T09:42:14Z","timestamp":1354700534000},"page":"170-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations"],"prefix":"10.1016","volume":"23","author":[{"given":"Georgina","family":"Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hiscock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H.","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan Y.","family":"Manzur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"de Vile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Beeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Robb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2012.11.004_b0005","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1126\/science.1130837","article-title":"Dok-7 mutations underlie a neuromuscular junction synaptopathy","volume":"313","author":"Beeson","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.nmd.2012.11.004_b0010","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/brain\/awm072","article-title":"Clinical features of the DOK7 neuromuscular junction synaptopathy","volume":"130","author":"Palace","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2012.11.004_b0015","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/brain\/awm068","article-title":"Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes","volume":"130","author":"Muller","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2012.11.004_b0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ana.21408","article-title":"Engel AG Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients","volume":"64","author":"Selcen","year":"2008","journal-title":"Ann Neurol"},{"issue":"19","key":"10.1016\/j.nmd.2012.11.004_b0085","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1212\/WNL.0b013e3181dd43bf","article-title":"Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7","volume":"74","author":"Lashley","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2012.11.004_b0030","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.nmd.2009.09.008","article-title":"Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations","volume":"19","author":"Schara","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2012.11.004_b0035","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","article-title":"Daily salbutamol in young patients with SMA type II","volume":"18","author":"Pane","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2012.11.004_b0090","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-010-9085-7","article-title":"Successful use of albuterol in a patient with central core disease and mitochondrial dysfunction","author":"Schreuder","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2012.11.004_b0045","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.57.8.1434","article-title":"Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy","volume":"57","author":"Kissel","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2012.11.004_b0050","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/mus.22176","article-title":"Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia","volume":"44","author":"Liewluck","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2012.11.004_b0055","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1152\/physrev.00028.2007","article-title":"Role of \u03b2-adrenoreceptor signaling in skeletal muscle: implications for muscle wasting and disease","volume":"88","author":"Lynch","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.nmd.2012.11.004_b0060","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1126\/science.1127142","article-title":"The muscle protein Dok-7 is essential for neuromuscular synaptogenesis","volume":"312","author":"Okada","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.nmd.2012.11.004_b0065","first-page":"25","article-title":"Dok7\/MuSK signalling and a congenital myasthenic syndrome","volume":"27","author":"Yamanashi","year":"2008","journal-title":"Acta Myologica"},{"key":"10.1016\/j.nmd.2012.11.004_b0095","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.092361","article-title":"Rapsyn mediates subsynaptic anchoring of PKA type I and stabilisation of acetylcholine receptor in vivo","author":"Choi","year":"2012","journal-title":"J Cell Sci"},{"key":"10.1016\/j.nmd.2012.11.004_b0075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1440-1681.2009.05312.x","article-title":"Lynch GS novel role for \u03b2-adrenergic signalling in skeletal muscle growth, development and regeneration","volume":"37","author":"Ryall","year":"2010","journal-title":"Clin Expt Pharmacol Physiol"},{"key":"10.1016\/j.nmd.2012.11.004_b0080","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.molcel.2010.06.007","article-title":"The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization","volume":"39","author":"Bergamin","year":"2010","journal-title":"Mol Cell"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896612006712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896612006712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:00:52Z","timestamp":1760774452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896612006712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0960896612006712"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2012.11.004","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2012.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V.","name":"copyright","label":"Copyright"}]}}